PCRX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Pacira BioSciences, Inc. had $726M of revenue in fiscal 2025, up 3.6% on the year before. Over five years, revenue changed +11.1% a year on average.
Last close Β· Oct 26, 2026
$36.38
+$14.64 (+67.34%) past year
Hi! I read Pacira BioSciences, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+3.6%
Only a little. Sales grew 3.6% last year.
Does it make a profit?
1.0%
A little. It keeps 1.0% of every sale as profit.
Does profit turn into cash?
18.8%
Yes. 18.8% of sales ends up as free cash.
Is debt under control?
1.2x
Keep an eye on it. Repaying its debt would take 1.2 years of operating profit.
How healthy are the accounts?
9 / 9
Solid. It passes 9 of 9 health tests.
How is the share priced?
101.1x
One share costs 101.1 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Pacira BioSciences, Inc. had $726M of revenue in fiscal 2025, up 3.6% on the year before. Over five years, revenue changed +11.1% a year on average. Its operating margin was 2.6%, up 13.1Β pts: of every 100 in sales, about 3 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Pacira BioSciences, Inc. made $7.0M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $137M in fiscal 2025, 18.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Pacira BioSciences, Inc. returned $148M to shareholders in fiscal 2025, 109% of free cash flow. The diluted share count fell 2.6%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $2.8M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$2.8M
5 insiders
Of sales under plans
100%
$2.7M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 8, 2026 | Lauren RikerSenior Vice President, Finance | Sold plan | 6,000 | $36.32 | $0.2M | Form 4 |
| Aug 17, 2026 | Jonathan SloninChief Medical Officer | Sold plan | 3,040 | $23.23 | $0.1M | Form 4 |
| Jun 11, 2026 | Lauren RikerSenior Vice President, Finance | Sold plan | 6,115 | $23.50 | $0.1M | Form 4 |
| Jun 4, 2026 | Kristen WilliamsChief Administrative Officer | Sold plan | 10,259 | $22.27 | $0.2M | Form 4 |
| Apr 23, 2026 | Shawn CrossChief Financial Officer | Sold plan | 12,941 | $25.16 | $0.3M | Form 4 |
| Apr 22, 2026 | Shawn CrossChief Financial Officer | Sold plan | 1,500 | $25.01 | $0.0M | Form 4 |
| Apr 21, 2026 | Shawn CrossChief Financial Officer | Sold plan | 2,845 | $25.01 | $0.1M | Form 4 |
| Apr 20, 2026 | Shawn CrossChief Financial Officer | Sold plan | 7,714 | $25.14 | $0.2M | Form 4 |
| Mar 17, 2026 | Jonathan SloninChief Medical Officer | Sold plan | 3,261 | $22.82 | $0.1M | Form 4 |
| Mar 17, 2026 | Mark FroimsonDirector | Sold | 500 | $21.81 | $0.0M | Form 4 |
| Feb 2, 2026 | Lauren RikerSenior Vice President, Finance | Sold plan | 4,000 | $20.81 | $0.1M | Form 4 |
| Feb 2, 2026 | Kristen WilliamsChief Administrative Officer | Sold plan | 13,137 | $20.53 | $0.3M | Form 4 |
| Jan 5, 2026 | Lauren RikerSenior Vice President, Finance | Sold plan | 1,416 | $24.24 | $0.0M | Form 4 |
| Dec 10, 2025 | Shawn CrossChief Financial Officer | Sold plan | 9,104 | $25.14 | $0.2M | Form 4 |
| Dec 9, 2025 | Shawn CrossChief Financial Officer | Sold plan | 15,896 | $25.03 | $0.4M | Form 4 |
| Nov 17, 2025 | Jonathan SloninChief Medical Officer | Sold plan | 3,960 | $24.09 | $0.1M | Form 4 |
| Nov 10, 2025 | Shawn CrossChief Financial Officer | Sold plan | 12,060 | $22.09 | $0.3M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Pacira BioSciences, Inc. owes $134M more than it holds in cash, about 1.2 years of operating profit.
Cash, debt and the ratios that show how comfortably Pacira BioSciences, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $656M | $289M | $279M | $485M | $238M |
| Debt incl. finance leases | β | $689M | $522M | $787M | $372M |
| Net debt / EBITDA | β | 2.6x | 1.5x | 55.9x | 1.2x |
| Debt / equity | β | 0.9x | 0.6x | 1.0x | 0.5x |
| Interest coverage | 2.8x | 1.5x | 4.3x | β4.4x | 1.1x |
| Current ratio | 1.7x | 3.4x | 5.2x | 2.4x | 4.5x |
| Quick ratio | 1.5x | 2.7x | 4.2x | 2.0x | 3.3x |
| Total assets | $2.1B | $1.7B | $1.6B | $1.6B | $1.3B |
| Total liabilities | $1.3B | $906M | $704M | $775M | $572M |
| Shareholders' equity | $730M | $775M | $870M | $778M | $693M |
| Net debt (β = net cash) | β | $401M | $244M | $302M | $134M |
KIRA Β· Its return on capital was 1.5%: every 100 invested in the business earned about 2 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Pacira BioSciences, Inc. passes 9 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 8 | 6 / 8 | 4 / 8 | 3 / 8 | 4 / 8 | 5 / 8 | 8 / 9 | 5 / 9 | 9 / 9 |
| Accruals ratio | β18.2% | β11.8% | β7.5% | β10.7% | 6.5% | β5.0% | β6.9% | β6.9% | β18.5% | β10.3% |
| Altman Z'' | 1.22 | 2.05 | 3.21 | 1.68 | 2.64 | 1.62 | 2.22 | 3.17 | 2.14 | 3.08 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $276M | $287M | $337M | $421M | $430M | $542M | $667M | $675M | $701M | $726M |
| Gross profit | $166M | $199M | $250M | $314M | $312M | $401M | $468M | $490M | $531M | $577M |
| Research and development | $45.7M | $57.3M | $55.7M | $72.1M | $59.4M | $55.5M | $84.8M | $76.3M | $81.6M | $117M |
| Operating income | β$32.0M | β$24.9M | $15.9M | $10.5M | $46.4M | $89.9M | $60.0M | $87.7M | β$73.4M | $19.2M |
| Interest expense | $7.1M | $18.0M | $21.9M | $23.6M | $25.7M | $31.8M | $40.0M | $20.3M | $16.6M | $17.4M |
| Pretax income | β$37.8M | β$42.5M | β$0.4M | β$10.7M | $20.1M | $56.4M | $13.3M | $61.7M | β$63.1M | $16.9M |
| Income tax | $0.1M | $0.1M | $0.0M | $0.3M | β$125M | $14.4M | β$2.6M | $19.7M | $36.5M | $9.8M |
| Net income | β$37.9M | β$42.6M | β$0.5M | β$11.0M | $146M | $42.0M | $15.9M | $42.0M | β$99.6M | $7.0M |
| Diluted EPS | β$1.02 | β$1.07 | β$0.01 | β$0.27 | $3.33 | $0.92 | $0.34 | $0.89 | β$2.15 | $0.16 |
| Diluted shares | 0.04B | 0.04B | 0.04B | 0.04B | 0.04B | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | $33.5M | $17.8M | $48.9M | $70.5M | $77.0M | $126M | $145M | $155M | $189M | $152M |
| Capital expenditure | $24.7M | $19.3M | $14.5M | $10.2M | $37.8M | $45.9M | $30.1M | $15.2M | $10.6M | $15.3M |
| Free cash flow | $8.7M | β$1.5M | $34.4M | $60.4M | $39.2M | $79.9M | $115M | $139M | $179M | $137M |
| Depreciation and amortization | $12.9M | $13.8M | $13.2M | $19.6M | $19.9M | $28.5M | $91.5M | $75.6M | $78.8M | $91.0M |
| Stock-based compensation | $31.2M | $31.6M | $31.7M | $33.7M | $39.9M | $42.2M | $48.1M | $47.9M | $51.2M | $57.5M |
| Acquisitions | β | $0.0M | $0.0M | $118M | $0.0M | $420M | $0.0M | $0.0M | $0.0M | $16.7M |
| Share buybacks | β | β | β | β | β | β | $0.0M | $0.0M | $25.0M | $148M |
| Dividends and buybacks | β | β | β | β | β | β | $0.0M | $0.0M | $25.0M | $148M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $173M | $311M | $383M | $292M | $522M | $656M | $289M | $279M | $485M | $238M |
| Total debt | $109M | β | β | β | β | β | $689M | $522M | $787M | $372M |
| Current assets | $243M | $391M | $478M | $409M | $652M | $866M | $498M | $510M | $745M | $548M |
| Current liabilities | $44.8M | $56.2M | $60.7M | $108M | $253M | $521M | $148M | $97.4M | $310M | $121M |
| Inventory | $31.3M | $41.4M | $48.6M | $58.3M | $64.7M | $98.6M | $96.1M | $104M | $125M | $153M |
| Property and equipment, net | $101M | $107M | $109M | $105M | $137M | $188M | $184M | $174M | $167M | $141M |
| Goodwill | $46.7M | $55.2M | $62.0M | $99.5M | $99.5M | $145M | $163M | $163M | $0.0M | $20.2M |
| Intangible assets | $0.0M | β | $0.0M | $104M | $96.5M | $624M | $541M | $483M | $426M | $368M |
| Total assets | $391M | $628M | $689M | $831M | $1.3B | $2.1B | $1.7B | $1.6B | $1.6B | $1.3B |
| Total liabilities | $172M | $349M | $368M | $476M | $655M | $1.3B | $906M | $704M | $775M | $572M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $219M | $279M | $321M | $355M | $620M | $730M | $775M | $870M | $778M | $693M |
| Margins | ||||||||||
| Gross margin | 60.2% | 69.3% | 74.3% | 74.7% | 72.7% | 74.1% | 70.1% | 72.6% | 75.7% | 79.4% |
| Operating margin | β11.6% | β8.7% | 4.7% | 2.5% | 10.8% | 16.6% | 9.0% | 13.0% | β10.5% | 2.6% |
| EBITDA margin | β6.9% | β3.9% | 8.6% | 7.1% | 15.4% | 21.9% | 22.7% | 24.2% | 0.8% | 15.2% |
| Net margin | β13.7% | β14.9% | β0.1% | β2.6% | 33.9% | 7.8% | 2.4% | 6.2% | β14.2% | 1.0% |
| FCF margin | 3.2% | β0.5% | 10.2% | 14.3% | 9.1% | 14.7% | 17.3% | 20.7% | 25.5% | 18.8% |
| Returns | ||||||||||
| Return on capital | β16.3% | β | β | β | β | β | 5.1% | 5.4% | β5.4% | 1.5% |
| Return on capital employed | β9.2% | β4.4% | 2.5% | 1.4% | 4.5% | 5.8% | 3.9% | 5.9% | β5.9% | 1.7% |
| Return on equity | β17.3% | β17.1% | β0.2% | β3.3% | 29.9% | 6.2% | 2.1% | 5.1% | β12.1% | 1.0% |
| Return on assets | β9.7% | β8.4% | β0.1% | β1.4% | 13.8% | 2.5% | 0.8% | 2.6% | β6.4% | 0.5% |
| Return on tangible equity | β22.0% | β19.0% | β0.2% | β7.3% | 34.4% | β | 22.3% | 18.8% | β28.3% | 2.3% |
| Growth | ||||||||||
| Revenue growth | β | 3.7% | 17.7% | 24.8% | 2.0% | 26.0% | 23.1% | 1.2% | 3.9% | 3.6% |
| Net income growth | β | β | β | β | β | β71.2% | β62.1% | 163.7% | β337.3% | β |
| EPS growth | β | β | β | β | β | β72.4% | β63.0% | 161.8% | β341.6% | β |
| FCF growth | β | β116.9% | β | 75.7% | β35.0% | 103.5% | 44.3% | 21.1% | 28.1% | β23.5% |
| Share count change | β | 6.9% | 2.8% | 1.5% | 5.2% | 4.5% | 2.0% | 11.7% | β11.0% | β2.6% |
| Financial health | ||||||||||
| Net debt / EBITDA | β | β | β | β | β | β | 2.6x | 1.5x | 55.9x | 1.2x |
| Debt / equity | 0.5x | β | β | β | β | β | 0.9x | 0.6x | 1.0x | 0.5x |
| Interest coverage | β4.5x | β1.4x | 0.7x | 0.4x | 1.8x | 2.8x | 1.5x | 4.3x | β4.4x | 1.1x |
| Current ratio | 5.4x | 7.0x | 7.9x | 3.8x | 2.6x | 1.7x | 3.4x | 5.2x | 2.4x | 4.5x |
| Quick ratio | 4.7x | 6.2x | 7.1x | 3.3x | 2.3x | 1.5x | 2.7x | 4.2x | 2.0x | 3.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 8.9% | 6.7% | 4.3% | 2.4% | 8.8% | 8.5% | 4.5% | 2.2% | 1.5% | 2.1% |
| Stock comp / revenue | 11.3% | 11.0% | 9.4% | 8.0% | 9.3% | 7.8% | 7.2% | 7.1% | 7.3% | 7.9% |
| Payouts / FCF | β | β | β | β | β | β | 0.0% | 0.0% | 14.0% | 108.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 6.0 | 4.0 | 3.0 | 4.0 | 5.0 | 8.0 | 5.0 | 9.0 |
| Altman Z'' | 1.2 | 2.1 | 3.2 | 1.7 | 2.6 | 1.6 | 2.2 | 3.2 | 2.1 | 3.1 |
| Accruals ratio | β18.2% | β11.8% | β7.5% | β10.7% | 6.5% | β5.0% | β6.9% | β6.9% | β18.5% | β10.3% |
Source: SEC EDGAR XBRL filings (CIK 0001396814). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
